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What is already known? 
· Exercise interventions are effective in lowering systolic blood pressure. 
 
What are the new findings? 
· Across all populations, individuals who receive antihypertensive medications tend to 
achieve greater reductions in SBP than those who adopt structured exercise regimens.  
· In populations with hypertension, different types of exercise interventions appear 
equally effective as most antihypertensive medications.  
· Structured exercise has not been evaluated as extensively as antihypertensive 
medications. 
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Abstract  
 
Objective: To compare the effect of exercise regimens and medications on systolic blood 
pressure (SBP).  
 
Data sources: Medline (via Pubmed) and the Cochrane Library. 
 
Eligibility criteria: Randomized controlled trials (RCTs) of angiotensin convertase enzyme 
inhibitors (ACE-I), angiotensin-2 receptor blockers (ARB), beta-blockers, calcium channel 
blockers (CCBs), and diuretics were identified from existing Cochrane reviews. A previously 
published meta-analysis of exercise interventions was updated to identify recent RCTs that 
tested the SBP-lowering effects of endurance, dynamic resistance, isometric resistance, and 
combined endurance and resistance exercise interventions (up to September 2018).  
 
Design: Random-effects network meta-analysis. 
 
Outcome: Difference in mean change from baseline SBP between comparator treatments 
(change from baseline in one group minus that in the other group) and its 95% credible 
interval (95% CrI), measured in millimeter mercury (mmHg). 
 
Results: We included a total of 391 RCTs, 197 of which evaluated exercise interventions 
(10,461 participants) and 194 evaluated antihypertensive medications (29,281 participants). 
No RCTs compared directly exercise against medications. While all medication trials 
included hypertensive populations, only 56 exercise trials included hypertensive participants 
(³140 mm Hg), corresponding to 3,508 individuals. In a 10% random sample, risk of bias 
was higher in exercise RCTs, primarily due to lack of blinding and incomplete outcome data. 
In analyses that combined all populations, antihypertensive medications achieved higher 
reductions in baseline SBP compared to exercise interventions (mean difference: -3.96 
mmHg, 95% CrI: -5.02 to -2.91). Compared to control, all types of exercise (including 
combination of endurance and resistance) and all classes of antihypertensive medications 
were effective in lowering baseline SBP. Among hypertensive populations, there were no 
detectable differences in the SBP-lowering effects of ACE-I, ARB, beta-blocker, and diuretic 
medications when compared to endurance or dynamic resistance exercise. There was no 
detectable inconsistency between direct and indirect comparisons. Although there was 
evidence of small-study effects, this affected both medication and exercise trials.  
 
Conclusions: The effect of exercise interventions on SBP remains under-studied, especially 
among hypertensive populations. Our findings confirm modest but consistent reductions in 
SBP in many studied exercise interventions across all populations but individuals receiving 
medications generally achieved greater reductions than those following structured exercise 
regimens. Assuming equally reliable estimates, the SBP-lowering effect of exercise among 
hypertensive populations appears similar to that of commonly used antihypertensive 
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medications. Generalisability of these findings to real-world clinical settings should be 
further evaluated.   
 5 
Introduction 
 
High systolic blood pressure (SBP) is a major modifiable risk factor for cardiovascular 
disease.1 Individuals with high SBP are at elevated risk of cardiovascular disease and death2–4 
and high SBP is the leading cause of death and disability around the world.5 Over the past 
half century, several classes of pharmacological treatment options have received approval to 
be prescribed for blood pressure-lowering.6 The mortality and morbidity benefits of these 
antihypertensive medication options have been extensively documented in randomized 
controlled trials (RCTs) and meta-analyses.7,8  
 
As the burden of cardiovascular disease continues to rise,9 the use of medications targeting 
high blood pressure is sharply increasing.10 In England, the number of adults taking blood 
pressure-lowering medications increased by approximately 50% from 2006 to 2016.11 This 
upward trend will likely increase, as recent changes to major clinical practice guidelines 
developed by prominent organisations such as the American Heart Association and the 
American College of Cardiology (AHA/ACC) have lowered the SBP threshold for the 
definition of hypertension.12 These changes are expected to markedly increase the number of 
people labelled as having hypertension and treated with medications.13,14  
 
Such an increase may lead to inadvertent adverse events at the population level, as the 
number of people taking multiple medications continues to rise;15 polypharmacy represents a 
major risk factor for drug-related morbidity and mortality.16 Prescription drugs also 
contribute to rising health care expenditures. Spending on medications accounts for about 
18% of total health spending on average across European countries.17 Recent increases in 
medication-related costs have prompted significant policy and clinical attention to the 
comparative effectiveness of new and existing medications.18 Meanwhile, relatively little 
attention has been given to promote wider adoption of non-pharmacological interventions 
such as exercise.  
 
Exercise interventions have indisputable benefits for cardiovascular disease and beyond.19,20 
According to a pooled analysis of observational cohort studies, men and women with high 
levels of leisure time physical activity had a 24% and 27% lower risk of cardiovascular 
disease, respectively, than men and women with low levels of physical activity.21 In addition, 
previous meta-analyses of RCTs showed that exercise is effective in improving established 
cardiovascular risk factors: exercise interventions reduce waist circumference,22 improve 
HbA1c,23 lower serum triglycerides,24 and increase high-density lipoprotein.25  
 
Exercise also has well-documented benefits in lowering SBP.26 In a previous meta-analysis of 
93 RCTs conducted among 5,223 healthy adults, SBP was reduced after endurance, dynamic 
resistance and isometric resistance exercise regimens.27 Although recent AHA/ACC 
guidelines emphasize the role of lifestyle interventions, including exercise, in the 
management and treatment of hypertension, they consider pharmacological and non-
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pharmacological interventions in isolation.12 It would be very important to evaluate the 
comparative SBP-lowering effects of exercise and medication interventions. 
 
In a previous meta-epidemiological study, we evaluated the comparative effectiveness of 
pharmacological and non-pharmacological interventions on mortality.28 We found structured 
exercise interventions to be equally effective as several frequently used medications in terms 
of their mortality benefits in the secondary prevention of coronary heart disease, 
rehabilitation after stroke, treatment of heart failure, and prevention of diabetes. However, 
the amount of evidence on the mortality benefits of exercise was considerably smaller than 
that on medications. In addition, there was a paucity of available information on the 
‘formulation’ and ‘dose’ of different types of exercise interventions and also on the 
characteristics of people that stood to benefit from such interventions.  
 
In this study, we set out to perform a network meta-analysis to systematically compare the 
SBP-lowering effects of exercise and medications. Our objective was to evaluate how 
different types and intensities of exercise fared against different classes and doses of 
antihypertensive medications in terms of lowering baseline SBP levels. In addition, we 
assessed the comparative SBP-lowering effects of exercise and medications specifically 
among hypertensive populations.  
 
Methods 
 
Identification of available evidence 
As previously,28 we identified the relevant body of evidence in three steps. First, one 
researcher (HN) searched Medline via Pubmed for the most recently published 
comprehensive meta-analyses of RCTs evaluating the effectiveness of exercise interventions 
on lowering SBP (see search strategy in Appendix 1).  
 
Second, one researcher (HN up to August 2017 and MSK from August 2017 to September 
2018) searched Medline via Pubmed to identify recently published RCTs of exercise 
interventions aimed at lowering SBP that were published after the end date of electronic 
database search in the meta-analyses identified in step one (see search strategy in Appendix 2). 
Accordingly, our search covered the period from February 2012 to September 2018. Two 
researchers (SAS and HN, up to August 2017) and one researcher (MSK, from August 2017 
to September 2018) screened identified titles and abstracts according to prespecified 
eligibility criteria. Participants of interest included adults (with or without hypertension) with 
no cardiovascular disease, cerebrovascular disease, diabetes, or other chronic conditions such 
as cancer. Eligible interventions were any form of structured exercise of any frequency, 
duration or intensity. Eligible comparator interventions included usual practice (no exercise), 
other exercise regimens, or medications. Studies were included if they lasted at least four 
weeks and reported SBP at baseline and follow-up (or change from baseline) for intervention 
and comparator arms or the difference in means between the two arms. One researcher 
(MB) contacted the corresponding authors of recently published RCTs to obtain missing 
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outcome data in the papers. Following title and abstract screening, three researchers (MB, 
MSK and HN) reviewed potentially relevant full text articles to determine study eligibility. 
Disagreements were resolved by consensus.  
 
Third, one researcher (MSK) searched the Cochrane Library to identify published meta-
analyses of RCTs of prescription medications aimed at lowering SBP with similar participant 
populations to those in the meta-analyses of exercise trials (i.e., adults in whom the blood-
pressure lowering effect of an intervention can be observed, excluding individuals with other 
conditions potentially causing hypertension, such as renal failure). Comparators in eligible 
medication trials included placebo, other medications, doses, or usual care. The list of 
relevant medication classes was identified using the clinical practice guidelines developed by 
the National Institute for Health and Care Excellence (NICE)29 and European Society of 
Hypertension/European Society of Cardiology (ESH/ESC).30 We also used the British 
National Formulary (BNF) to determine the eligible doses of individual antihypertensive 
medications.31 Only trial arms of RCTs of medications from guideline-recommended 
medication classes and BNF-approved doses were eligible for inclusion in our review. We 
did not run additional searches to update the list of medication RCTs included in previous 
meta-analyses, since they were deemed to be sufficiently up-to-date and, in contrast to 
exercise trials, the amount of evidence for medication trials was already very large.  
 
Data extraction 
We adopted a 2-tiered data extraction strategy. For eligible RCTs of medications, we relied 
on the information reported in the published Cochrane meta-analyses. We divided the 
sample of RCTs and two researchers (MSK and MB) extracted information on author name, 
trial reference, publication year, interventions (including dose), comparators, sample size 
(total number of randomly assigned participants or total number of participants with 
outcome measurement) per trial arm, and outcome data.  
 
For eligible RCTs of exercise interventions, we carried out primary data collection from each 
publication. In addition to the data items captured from medication RCTs, we collected 
detailed information on the characteristics of participants (e.g., mean age, proportion female) 
and interventions (type, intensity, frequency, duration). In terms of outcome data, we 
focused on SBP, as it has been consistently associated with cardiovascular risk in 
epidemiological and experimental studies.12 SBP is also more commonly reported than 
diastolic blood pressure.27 We set out to extract the mean change from baseline SBP levels 
and its standard deviation in each trial arm. When the mean change from baseline was not 
available, we obtained the mean and standard deviation of SBP levels at baseline and follow-
up in each arm and thus calculated the mean change from baseline for each study.  
 
Data on the standard deviation of change from baseline SBP were rarely available. We 
therefore relied on standard errors, 95% confidence intervals, p-values, or t statistics to 
calculate standard deviations, as recommended by the Cochrane Handbook.32 When no 
information was available to calculate standard deviations, we imputed missing values by 
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using a correlation coefficient of 0.8 between baseline and follow-up SBP. We tested the 
sensitivity of our findings to different correlation coefficients and confirmed the consistency 
of results across different sets of analyses (see Appendix 4). Two researchers extracted 
outcome data (SAS & MB up to August 2017 and HN & MSK from August 2017 to 
September 2018) and another researcher independently appraised the accuracy of the 
information.  
 
Categorization of available evidence 
Exercise was defined as a subset of physical activity that is structured and repetitive with the 
objective of improving or maintaining physical fitness.33 We divided exercise interventions 
into four major categories: (1) endurance, (2) dynamic resistance, (3) isometric resistance, and 
(4) a combination of endurance and dynamic resistance.27 Endurance exercise included 
interventions aimed at increasing heart rate and energy expenditure. Examples of endurance 
exercise included walking, jogging, running, cycling, and swimming. Interval training was 
considered as endurance exercise. We labeled exercise interventions as resistance training if 
they were aimed at increasing muscular strength and power. Strength training with dumbbells 
was a typical form of resistance exercise. We categorized exercise interventions as isometric 
exercise if they involved sustained contraction against an immovable load.  
 
Intensity of exercise interventions was categorized into low, moderate, and high using the 
classification developed by the American College of Sports Medicine.34 The majority of 
exercise RCTs reported relevant information such as percent of heart rate reserve (% HRR), 
percent of maximal heart rate (% HRmax), percent of maximal oxygen uptake (% VO2 max), or 
percent of one repetition maximum (% 1RM) to categorize the relative or absolute intensity 
of exercise interventions. In cases where such information was not available, we relied on the 
study authors’ reporting to determine the intensity of physical activity (n=9).  
 
Individual medications were categorized into the following antihypertensive medication 
classes: angiotensin convertase enzyme inhibitors (ACE-I), angiotensin-2 receptor blockers 
(ARB), beta-blockers, calcium channel blockers (CCB), and diuretics. Medications were also 
divided into low and high doses according to the BNF, assigning them to “low” if at or 
below the mid-point of recommended doses in the BNF and “high” if above the mid-point 
of recommended doses.  
 
We categorized exercise trials according to the study-level mean baseline SBP of the 
participant population. While the RCTs of antihypertensive medications included only 
hypertensive participants (with baseline SBP at or above 140 mmHg), exercise trials had 
more variable inclusion criteria. In our primary analysis, participant populations were labeled 
as “hypertensive” if exercise trials included adults with mean baseline SBP of at least 140 
mmHg, which was consistent with the original definition of hypertension until the changes 
introduced by the 2017 AHA/ACC guidelines.  
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We also considered additional cut-offs to define hypertension in two sensitivity analyses. In 
the first set of sensitivity analyses, we labeled populations in exercise RCTs as hypertensive if 
they had average SBP of at least 130 mmHg, which corresponds to the new blood pressure 
threshold to define hypertension in the 2017 AHA/ACC guidelines.12 In the second set of 
sensitivity analyses, we tested a cut-off of 150 mmHg for mean SBP in exercise trials, as this 
more closely matched the mean SBP of the trial populations in medication trials.  
 
Risk of bias assessment 
We used the Cochrane risk of bias tool to evaluate the internal validity of results in a 10% 
random sample of medication (n=20) and exercise RCTs (n=20) (Appendix 5).35 Two 
researchers (HN and MB) reviewed the publications of selected trials to determine whether 
the investigators used appropriate methods to (1) generate a random allocation sequence 
(selection bias), (2) conceal the sequence of treatment allocation from trial investigators and 
participants before the trial (selection bias), (3) mask participants and investigators from 
knowledge of treatment allocation during the trial (performance bias and detection bias), and 
(4) deal with missing outcome data (attrition bias). We consistently rated the selective 
outcome reporting domain as “unclear”, as there was inadequate information available in the 
trials to evaluate planned vs. reported outcomes.  
 
Statistical analysis 
We first qualitatively synthesized included trials and described the types of direct and indirect 
comparisons and their relative contributions to the overall body of evidence available.  
We then developed network diagrams to visualize the relative amount of available evidence 
on exercise and medications.36 Nodes represented different exercise and medications and 
lines connecting the nodes represented the direct head-to-head comparisons between 
interventions. In network diagrams, the size of each node and the thickness of each line 
connecting the nodes were proportional to the number of participants. All network diagrams 
were generated using Stata version 15.37  
 
To estimate the comparative effectiveness of exercise and medications on SBP-lowering, we 
performed network meta-analyses.38 Such analyses allow for comparing treatments that have 
not been directly compared to each other in head-to-head studies.39 They can also combine 
evidence obtained from direct and indirect comparisons, thereby improving the precision of 
treatment effect estimates.40,41 Similar to pair-wise meta-analyses, network meta-analyses 
preserve the random allocation of participants to different arms within each trial, however, 
they compare multiple interventions by combining all available comparisons between 
treatments across trials, utilizing the totality of the available evidence.42  
 
Study-level treatment effects were combined using Bayesian Markov chain Monte Carlo 
methods in WinBUGS version 1.4.3.43 We used the model developed by Dias and colleagues 
for the NICE Decision Support Unit.44–46 Our base-case model assumed that the mean 
change from baseline in SBP per trial arm had a normal distribution. The relative effects 
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across trials making different comparisons were linked using the identity function. This 
model took into account the correlations between treatment effects within multi-arm trials.  
 
We used a random-effects model to perform the network meta-analyses, allowing for 
between-study heterogeneity.47 Our models therefore assumed that trial-specific treatment 
effects were drawn from a normal distribution, with a mean that was specific for each 
treatment comparison, and a common variance that was shared by all comparisons. We 
reported the mean treatment effect with 95% credible intervals (95% CrI) of every 
intervention relative to control and other interventions and the estimated between-study 
heterogeneity standard deviation with its 95% CrI.  
 
To test the consistency assumption of the network meta-analysis, we compared the fit of the 
base-case model to that of an inconsistency model.48,49 The latter model does not assume 
consistency between direct and indirect evidence and instead estimated independent mean 
treatment effects.50 We also examined each data point’s contribution to the residual deviance 
and compared the estimated between-study heterogeneity in each model. We assessed any 
improvements in fit or reductions in between-study heterogeneity in the inconsistency 
model, which would suggest potential inconsistency (see Appendix 6). We plotted the findings 
of this secondary analysis side-by-side with our base-case model that assumed consistency to 
compare the results of the two models. We visually inspected the findings and assessed for 
systematic differences from those obtained from our primary analyses (see Appendix 6).  
 
We compared the SBP-lowering effects of exercise and antihypertensive medications in three 
sets of analyses: (1) all exercise interventions vs. all antihypertensive medications; (2) 
different types of exercise interventions vs. different classes of medications; and (3) different 
intensities of exercise interventions vs. different doses of medications. We then repeated 
these analyses and compared the antihypertensive RCTs to a subset of exercise trials that 
only included hypertensive populations. 
 
We evaluated small-study effects by extending the regression-based approach proposed by 
Moreno and colleagues.51–53 We regressed the treatment effects against their standard errors 
and predicted the pooled effect size for an ideal study of infinite size (i.e., with zero standard 
error), assuming that smaller studies would be more biased than larger studies.54 This meta-
regression allowed for a different mean bias according to type of comparison (i.e., mean bias 
due to small-study effects was assumed to be different for RCTs evaluating the effect of 
exercise vs. control and medications vs. control).55  
 
We adopted non-informative prior distributions for treatment effects (normal (0, 10,000)) 
and the between-trial variance (uniform (0, 10)). Our analyses employed a long burn-in 
period (50,000 iterations) and follow-up period (100,000 iterations) to allow for convergence. 
We ran three chains with different sets of initial values. We visually inspected trace plots for 
key parameters for each analysis to assess convergence in terms of stability.  
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Results 
 
Evidence base for medications 
Using the Cochrane Library, we initially identified 14 potentially relevant meta-analyses of 
medication therapies aimed at lowering baseline SBP (Figure 1). Of these, we selected the 
most comprehensive meta-analyses within each medication class recommended by the NICE 
and ESH/ESC guidelines as first-line therapy for hypertension.56–63 In total, these meta-
analyses included 316 RCTs. We excluded the trials and trial arms of medications and 
medication dosages that were not indicated in the BNF. After these exclusions, we included 
194 medication RCTs, corresponding to 57 trials of ACE-inhibitors, 36 studies of ARBs, 63 
studies of beta-blockers, 9 studies of CCBs, and 46 studies of diuretics. 17 RCTs compared 
one medication class to another.  
 
Evidence base for exercise interventions 
Of 47 potentially relevant reviews of exercise interventions identified from Medline, we 
considered the meta-analysis conducted by Cornelissen and Smart to be the most 
comprehensive in terms of its study identification, selection, review, and synthesis methods.27 
This analysis relied on 93 RCTs published up to February 2012. We subsequently updated 
this review and identified 2,619 potentially relevant titles and abstracts published until 
September 2018 (Figure 1). We excluded 2,317 records that were irrelevant. Of 302 full-text 
articles, we included an additional 107 RCTs. In total, we ultimately included 197 RCTs of 
exercise interventions (see Appendix 3 for trial characteristics). 115 of these evaluated endurance 
training interventions including walking, running, cycling, or aquatic exercises; 30 RCTs 
evaluated dynamic resistance interventions; 10 evaluated isometric resistance exercises; and 
12 tested endurance and resistance training regimens in combination. The remaining 30 
RCTs compared one type of exercise intervention to another. No RCTs compared directly 
exercise against medications.  
 
Characteristics of exercise and medication RCTs 
RCTs of exercise interventions included substantially fewer participants; average sample size 
in exercise RCTs was 53 (range: 15-464) compared to 139 in RCTs of beta-blockers (7-1092), 
174 in studies of ACE-inhibitors (14-625), 188 for diuretics (24-2776), 185 for CCBs (15-
397), and 292 for ARBs (40-1369). Mean age ranged from 50.4 for exercise trials to 55.0 for 
ARB and diuretics trials. On average, a higher proportion of participants were women in 
RCTs of exercise interventions (61%) compared to the proportion of women participants in 
RCTs of medications (ranging from 39% for ARBs to 47% for beta-blockers). While the 
mean SBP at baseline was 132 mmHg for participants in the RCTs of exercise interventions, 
it was consistently over 150 mmHg in medication RCTs (Table 1).  
 
Distribution of participants in exercise and medication RCTs 
In total, 39,742 participants were included in RCTs testing the SBP-lowering effects of 
medications and exercise interventions. While 29,281 participants were included in 
medication trials, 10,461 were included in exercise RCTs (Figure 2a). On average, trials of 
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individual medication classes had more participants than those included in the RCTs of 
different types of exercise (Figure 2b). The majority of participants included in exercise 
RCTs were in trials evaluating the effect of endurance training, as compared to control or 
other exercise interventions (n=8,174). Relatively more participants were included in trials 
evaluating moderate-intensity exercise alone (n=4,675) compared to those testing low and 
high-intensity interventions (Figure 2c). 56 exercise trials included hypertensive participants 
(³140 mmHg), corresponding to 3,508 individuals (Figure 3). A total of 6,046 and 1,828 
participants were included in exercise RCTs with hypertensive populations when using a 
cutoff of 130 mmHg and 150 mmHg for mean baseline SBP, respectively.  
 
Risk of bias  
Figure 4 and Appendix 5 summarize the risk of bias in a 10% random sample of exercise 
and medication RCTs. 17/20 exercise RCTs were judged to be at high risk of performance 
and detection bias due to lack of blinding while only 1 medication RCT was at high risk of 
bias on this domain. Risk of attrition bias was also higher in exercise trials (5/20) compared 
to that in medication trials (0/20). Inadequate reporting complicated our assessments for 
selection bias with the majority of both exercise and medication trials rated at unclear risk of 
bias.    
 
Comparative effects on SBP 
Across all populations, antihypertensive medications (mean difference: -8.80 mmHg, 95% 
CrI: -9.58 to -8.02) and exercise interventions (-4.84, 95% CrI: -5.55 to -4.13) were both 
effective in lowering SBP from baseline as compared to control (Figure 5a). Populations 
receiving medications achieved greater reductions in SBP compared to those participating in 
physical activity interventions (-3.96, 95% CrI: -5.02 to -2.91).  
 
Compared to control, all types of exercise (endurance: -4.88, 95% CrI: -5.69 to -4.06; 
resistance: -3.50, 95% CrI: -4.91 to –2.09; isometric: -5.65, 95% CrI: -8.21 to -3.13; and 
combination of endurance and resistance: -6.49, 95% CrI: -8.17 to -4.82) and all classes of 
antihypertensive medications (ACE-I: -7.33, 95% CrI: -8.75 to -5.91; ARB: -8.14, 95% CrI: -
9.62 to -6.69; CCB: -10.58, 95% CrI: -12.03 to -9.14; and diuretic: -8.06, 95% CrI: -9.48 to -
6.64) were effective in lowering baseline SBP (Figure 5b).  
 
Overall, different types of structured exercise interventions achieved similar reductions from 
baseline (Table 2). One exception was the combination of endurance and resistance training, 
which was more effective in reducing baseline SBP than dynamic resistance alone (-2.99, 
95% CrI: -5.04 to -0.93). While different classes of antihypertensive medications were 
generally more effective than different types of exercise interventions, most medication 
classes (ACE-I, ARB, and diuretic) did not differ beyond chance from isometric resistance 
and combination of endurance and dynamic resistance exercises.  
 
Participants in low- (-4.60, 95% CrI: -6.51 to -2.69), moderate- (-5.41, 95% CrI: -6.37 to -
4.46), and high-intensity (-3.87, 95% CrI: -5.11 to -2.65) exercise groups achieved greater 
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reductions in baseline SBP than those in control groups (Figure 5c). Similarly, low- and 
high-dose medications were more effective than control, lowering baseline SBP by 8.29 
mmHg (95% CrI: -9.13 to -7.46) and 10.71 mmHg (95% CrI: -11.94 to -9.46), respectively. 
While a dose gradient was seen for medications, there was substantial uncertainty for effects 
of different exercise intensities.   
 
There was no detectable evidence of inconsistency in the network meta-analyses (Appendix 
6). In our small-study effects analysis, we found some evidence that smaller studies reported 
different results than those in larger studies for both exercise and medication interventions 
(Appendix 7). We observed similar model fit with both models according to total residual 
deviance and deviance information criterion. The estimated mean bias for exercise vs. 
control was -1.09 (95% CrI: -1.89 to -0.34) and -1.75 (95% CrI: -2.61 to -0.72) for 
medications vs. control; however, there was no meaningful reduction in between-study 
heterogeneity when we adjusted for small-study effects, suggesting that this adjustment did 
not necessarily explain the observed differences in effects across studies. Since the base-case 
model fitted well, inferences about observed improvements to model fit or lack thereof may 
be spurious. Regardless, models adjusted for small-study effects tended to produce smaller 
treatment effect estimates for both exercise and medication interventions. Appendix 7 
compares the base-case results with predicted effect size for an ideal study of infinite size for 
each intervention.  
 
Comparative effects on SBP among hypertensive populations (³140 mmHg) 
Compared to control, exercise reduced SBP by 8.96 mmHg (95% CrI: -10.27 to -7.64) 
among hypertensive populations (³ 140 mmHg) (Figure 5a). We did not observe a 
difference between the SBP-lowering effects of medications and exercise (0.18, 95% CrI: -
1.35 to 1.68).  
 
SBP was reduced (compared to control) by endurance (-8.69, 95% CrI: -10.13 to -7.25), 
dynamic resistance (-7.23, 95% CrI: -10.58 to -3.87), and their combination (-13.51, 95% CrI: 
-16.55 to -10.45), while the 95% CrI included the null for isometric resistance (-4.92, 95% 
CrI: -10.28 to 0.38) (Figure 5b). Overall, different types of exercise interventions appeared 
similar to medication interventions in terms of their SBP-lowering effects (Table 2).  
 
Hypertensive populations participating in moderate- and high-intensity exercise interventions 
achieved greater reductions in SBP compared to those in control groups (Figure 5c). There 
were no detectable differences between different intensities of exercise and different doses of 
medication interventions, however these analyses should be interpreted with caution given 
the wide 95% CrIs.  
 
Sensitivity analyses with different hypertension cut-offs 
Figure 6 and Appendix 8 show the findings of sensitivity analyses comparing the SBP-
lowering effects of exercise and medication interventions at different hypertension cut-offs. 
Overall, exercise interventions appeared more effective as we restricted the sample of 
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exercise trials included in the analysis to those with more hypertensive populations. For 
example, endurance interventions, compared to control, reduced baseline SBP by 4.88 (95% 
CrI: (-5.69, -4.06) in the base-case analysis; respective reductions were 6.84 (-7.90 to -5.76) in 
trials with ³130 mmHg; 8.70 (-10.13 to -7.25) with ³140 mmHg, and 10.74 (-12.70 to -8.77) with 
³150 mmHg. There was substantial uncertainty in relative treatment effects when using a cut-off 
of ³150 mmHg.  
 
Discussion 
 
In this study, we compared the SBP-lowering effects of commonly used antihypertensive 
medications and exercise interventions. We found that structured exercise was often 
evaluated in fewer and smaller trials than medications. While the number of participants 
included in exercise trials accounted for approximately one quarter of the total in medication 
trials, only one tenth of the overall hypertensive population (using a 140 mmHg cut-off) 
came from the exercise trials. Our analyses that synthesized the results of 391 RCTs 
including 39,742 participants showed that individuals receiving medications achieved greater 
reductions in SBP than those following structured exercise regimens. However, different 
types of exercise interventions appeared equally effective as most antihypertensive 
medications when we limited our analyses to trials in populations with high SBP. The 
effectiveness of exercise increased as we adopted higher SBP cut-offs to define hypertension.  
 
Comparison with other studies in the literature 
To the best of our knowledge, our study is the first formal evaluation of the comparative 
effectiveness of exercise and medications on SBP. However, a large number of previous 
systematic reviews and meta-analyses have examined the SBP-lowering effects of 
medications8,64–67 and exercise separately.27,68–72 Similar to other reviews, our study identified 
a diverse set of exercise interventions that varied in terms of their formulation, intensity, 
frequency, and duration. Aerobic endurance was the most frequently studied type of exercise, 
followed by dynamic resistance.  
 
Our findings differed from the meta-analysis by Cornelissen and Smart in two key ways.27 
First, the magnitude of SBP reduction achieved with resistance training was considerably 
higher in our study, likely reflecting the large numbers of newer RCTs included in our study 
evaluating this type of exercise and having favourable results. This was particularly so when 
we limited our analyses to exercise RCTs with hypertensive populations. Second, we found 
compelling evidence that combining endurance and dynamic resistance training was effective 
in reducing SBP. The previous review had insufficient evidence on the effectiveness of 
combining endurance and dynamic resistance exercise. 
 
Implications for policy and practice 
These findings could be used to examine and improve the evidence base supporting exercise 
recommendations. Current exercise recommendations are primarily based on observational 
evidence and highly variable across different settings.73 For example, in the UK, the National 
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Health Service exercise guidelines for healthy adults 19 to 64 years of age recommend either 
(1) a combination of at least 150 minutes per week of moderate aerobic activity and strength 
training on 2 or more days a week or (2) a combination of 75 minutes per week of vigorous 
endurance activity and strength training on 2 or more days a week.74 Notably, while the 
guidelines specify the recommended duration of strength training, they do not specify its 
optimal volume and intensity. Examining and corroborating the evidence base behind these 
recommendations is not straightforward using the available exercise RCTs on SBP. For 
example, only a small subset of studies identified in our review tested the effectiveness of the 
combination of endurance and dynamic resistance training. Although these types of 
interventions were often effective, especially in hypertensive populations, their frequency and 
duration were not consistently reported to determine the optimal formulation and dose of 
physical activity to maximize its benefit. We also did not observe a dose-response 
relationship between exercise intensity and SBP reduction.  
 
Recent changes to major practice guidelines developed by ACC/AHA will substantially 
increase the number of people labelled as having hypertension.13,14 While our findings 
support previous calls to prescribe exercise as a treatment option for hypertension,75,76 
relatively little is known about the effectiveness and comparative effectiveness of 
implementation strategies for optimal exercise uptake.77–80 Health care systems are therefore 
ill-equipped to ensure effective adoption of and adherence to exercise prescriptions. Despite 
the availability of national guidelines promoting exercise, levels of physical activity remain 
stubbornly low worldwide.81 For example, an estimated 40% of adults in the Americas and 
many European counties are physically inactive.82,83 Given our findings that even low-
intensity exercise may be effective in reducing SBP, renewed attention is warranted to 
identify effective strategies to promote exercise.  
 
While our study suggests that exercise effectively lowers baseline SBP, the generalisability of 
these findings to real-world settings should be investigated further. Most exercise trials in our 
study included healthy adults with optimal or mildly elevated blood pressure. When 
participants had elevated SBP, exercise was often evaluated as an add-on to background 
antihypertensive therapy. Unlike trial populations in our review, the majority of individuals in 
actual clinical practice who are eligible for antihypertensive therapy have multiple chronic 
conditions and receive several medications. Substituting medication therapy with exercise 
prescriptions in these populations may therefore be challenging.85 The proportion of such 
patient populations who can adopt some meaningful amount of exercise is unknown. This is 
further compounded by the reporting quality of exercise trials. According to a recent 
analysis, descriptions of exercise interventions in hypertension trials were inadequately 
detailed for their replication in practice.84 Nevertheless, our findings can form the basis of 
evidence-based discussions between patients and their doctors about the SBP-lowering 
benefits of exercise. Although the effect of exercise is modest among individuals with 
moderately elevated SBP, providers should still have such discussions with their patients who 
are newly eligible for antihypertensive therapy as a result of recent changes to ACC/AHA 
guidelines.  
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Implications for research 
Studies comparing the effectiveness of medications and non-medication interventions are 
rare. Similar to our previous study,28 we did not identify any RCTs that directly compared the 
SBP-lowering effects of antihypertensive medications and structured training programs. To 
address this gap, future studies should adopt exercise as an active comparator in trials of 
interventions aimed at preventing, managing, or treating cardiovascular diseases. 
Pharmaceutical companies, which in recent years have sponsored the majority of clinical 
studies, currently have little incentive to design studies that compare their products to non-
medication alternatives.86 Encouraging sponsors to include established non-pharmacological 
alternatives in head-to-head trials will require buy-in from drug licensing agencies such as the 
Food and Drug Administration and European Medicines Agency, health technology 
assessment bodies such as NICE, research funders such as the National Institutes of Health 
in the US and National Institute for Health Research in the UK, and research ethics 
committees.  
 
In the absence of head-to-head RCTs that directly compare exercise and drug interventions, 
network meta-analyses can rely on existing studies and generate valuable evidence to inform 
policy and practice.87 Network meta-analyses that compare the benefits and harms of 
multiple interventions are increasingly common in the medical literature.88,89 However, most 
consider pharmacological or non-pharmacological interventions separately. Combining these 
bodies of literature in network meta-analyses could identify areas where exercise 
interventions should be considered as viable alternatives to medications. In areas where 
evidence is inconclusive or biased, network meta-analyses could help inform the design of 
future head-to-head RCTs.90 
 
Limitations 
This study had several limitations. First, our electronic searches were conducted in Medline 
and did not cover other relevant bibliographic databases. Therefore, we may have missed 
relevant RCTs of exercise interventions if they were published in journals not indexed in 
Medline. Still, our review covered almost twice as many RCTs as those included in the most 
comprehensive systematic review to date.  
 
Second, we did not update the list of studies included in the previously published meta-
analyses of antihypertensive medications, which were published from 2008 to 2016. 
However, it is unlikely that we missed additional RCTs of medications, as the majority of 
antihypertensive medications are off patent and there is no longer an active research agenda 
evaluating their SBP-lowering effects.   
 
Third, we relied on indirect evidence to determine the comparative SBP-lowering effects of 
exercise and medications. Such indirect comparisons could be biased if there is an imbalance 
in the distribution of unmeasured or unknown relative treatment modifiers across trials 
comparing different interventions.91 We summarised results from substantially 
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heterogeneous RCTs from different settings and time periods. Trials included diverse 
participant populations, intervention definitions, comparators, and outcome measurements. 
Findings of our network meta-analyses should hence be interpreted with caution.92 
Transitivity may be tenuous given the typically different levels of SBP in medication vs. 
exercise trials. However, when we tried to match trial populations more closely, the gap 
between medication and exercise in efficacy diminished. As we limited our analyses to more 
hypertensive populations, exercise interventions appeared more effective.   
 
Fourth, while we obtained clinically relevant relative treatment effects for antihypertensive 
medications, we may have underestimated the magnitude of SBP-lowering associated with 
exercise interventions. We excluded trials of medications and dosages that were considered 
to be ineffective or suboptimal by the BNF even though we did not exclude any exercise 
trials on this basis, as there is no equivalent body that is responsible for evaluating the 
effectiveness of structured exercise interventions and determining their suitability as 
treatment options in clinical practice.  
 
Fifth, our review shares the limitations of the studies on which it is based. Although we did 
not formally evaluate the internal validity of all included RCTs, we conducted a risk of bias 
assessment in a 10% random sample. Both exercise and medication trials had limitations in 
their reporting, which severely limited our accurate evaluation. We considered exercise trials 
to be at higher risk of performance and detection bias as compared to medication trials, 
primarily due to lack of blinding of investigators and participants in exercise trials. This may 
have greater implications on the reliability of estimates from exercise trials given the semi-
objective nature of SBP-lowering. However, a recent meta-epidemiological study found no 
significant association between treatment effects and adequate blinding in physical therapy 
trials.93 In contrast to the findings of a recent comprehensive review that showed a different 
level of reporting bias between meta-analyses of pharmacological and non-pharmacological 
interventions,94 we observed a similar relationship between trial size and magnitude of effect 
for both exercise and medications. Small-study effects may reflect publication bias, 
differential presence of quality issues in smaller trials, but also many other factors.95 
Although exercise trials tended to be smaller, antihypertensive medication trials were not 
immune to small-study effects, which could explain our findings. 
 
Exercise trials had several other methodological drawbacks. The majority of exercise trials 
included healthy adults with optimal blood pressure at baseline; reduction in blood pressure 
may be larger when the starting point is higher. Also, unlike antihypertensive medication 
trials, most exercise trials evaluated SBP only as secondary or tertiary outcomes; sample sizes 
were often too small to adequately control for confounding and produce reliable estimates of 
treatment effects; the composition of control arms was heterogeneous (e.g., some trials 
included exercise as an add-on to background antihypertensive therapy while others did not 
allow for such therapy); and the methods used to measure SBP varied considerably across 
trials (e.g., ranging from office-based measurement to ambulatory measurement). Similar to 
the findings of a recent analysis, reporting of harms associated with exercise interventions 
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was rare and inconsistent.95 Taken together, these variations highlight the need for a more 
standardised approach to the design, conduct, analysis, and reporting of exercise trials. 
Whether the reliability of estimates from exercise trials is similar to those from trials of 
antihypertensive medications should be evaluated in the future.  
 
Conclusions 
The effect of exercise interventions on SBP remains under-studied in relation to commonly 
used medications, especially among hypertensive populations. Many studied types and 
intensities of exercise interventions demonstrate modest but consistent reductions in SBP 
across diverse populations and settings. The SBP-lowering effects of exercise among 
hypertensive populations appear similar to that of commonly used antihypertensive 
medications but this is tempered by the observed differences in study population 
characteristics.  
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Figure legends 
 
Figure 1. Flow diagram of study identification and selection. 
 
Figure 2. Available evidence comparing (a) exercise vs. drugs; (b) different types of exercise vs. 
classes of drugs; and (c) different intensities of exercise vs. doses of drugs. The nodes represent 
different interventions and the lines connecting the nodes represent direct head-to-head 
randomized controlled trials comparing the interventions. The size of the node and the thickness 
of the line connecting the nodes are proportional to the number of participants. Combination 
refers to a combination of endurance exercise and dynamic resistance. Control refers to no 
exercise. 
 
Figure 3. Available evidence in hypertensive populations comparing (a) exercise vs. drugs; (b) 
different types of exercise vs. classes of drugs; and (c) different intensities of exercise vs. doses 
of drugs. Combination refers to a combination of endurance exercise and dynamic resistance. 
Control refers to no exercise. 
 
Figure 4. Risk of bias assessment of a 10% random selection of exercise and drug RCTs.  
 
Figure 5. Findings of network meta-analyses. Change from baseline systolic blood pressure 
(mmHg) and 95% CrI achieved with exercise and drug interventions as compared to control (no 
exercise): (a) exercise and drugs; (b) different types of exercise and classes of drugs; and (c) 
different intensities of exercise and doses of drugs. Findings of analyses pooling trials from all 
populations are shown in black; findings of analyses restricting exercise trials to those with 
mean systolic blood pressure ³140 mmHg are shown in white. Combination refers to a 
combination of endurance exercise and dynamic training.  
 
 
Figure 6. Findings of sensitivity network meta-analyses. Change from baseline SBP (mmHg) 
and 95% CrI achieved with different types of exercise and drug interventions as compared to 
control (no exercise) using different mean SBP cut-offs. Findings of analyses pooling trials 
from all populations are shown in black; findings of analyses restricting exercise trials to 
those with mean SBP ³130 mmHg are shown in grey; ³140 mmHg are shown in white; and 
³150 mmHg are shown in stripes. Combination refers to a combination of endurance exercise 
and dynamic training. 
